The Limits of BPC-157 Research: No Human Trials Yet
BPC-157 and Gut Health
544 papers
Of 544 published BPC-157 papers screened in a 2025 systematic review, only 1 clinical study met inclusion criteria. The rest were animal models.
Vasireddi et al., HSS Journal, 2025
Vasireddi et al., HSS Journal, 2025
View as imageBPC-157 is one of the most discussed peptides in the supplement and biohacking world. Online communities describe it as a near-universal healing compound. Influencer content claims it repairs tendons, heals gut linings, protects organs, and accelerates recovery from virtually any injury. The research database contains over 500 papers. And yet, as of early 2026, the total number of published human clinical trials with efficacy data can be counted on one hand.
That gap between the volume of animal research and the near-total absence of human data is the real BPC-157 story. Understanding why the gap exists, what it means, and what it does not mean is essential for anyone trying to evaluate this peptide's actual therapeutic potential.
Key Takeaways
- A 2025 systematic review screened 544 BPC-157 papers and found only 1 clinical study that met inclusion criteria; the remaining 35 included studies were preclinical animal models[1]
- The largest registered human trial (Phase I, 42 volunteers, PharmaCotherapia) was cancelled in 2016 with no data ever published
- Lee et al. (2024) published the most substantive human pilot study, testing BPC-157 in interstitial cystitis patients[2]
- The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, meaning it cannot be compounded commercially
- The majority of BPC-157 publications originate from a single research group at the University of Zagreb[3]
- No toxic or lethal dose has been identified in animal studies across a range of 6 ug/kg to 20 mg/kg[4]
What the Animal Evidence Actually Shows
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. The preclinical literature is extensive. Animal studies have demonstrated effects on wound healing, tendon repair, bone fractures, ligament injuries, muscle damage, liver protection, neuroprotection, and gastrointestinal mucosal integrity, among other endpoints.
Sikiric et al. (2025) published a comprehensive review in Pharmaceuticals summarizing decades of their group's work on BPC-157 as a cytoprotective peptide. The findings span multiple organ systems and injury models, consistently showing protective and regenerative effects in rats and mice.[4]
Demirtas et al. (2025) demonstrated protective effects of BPC-157 on liver, kidney, and lung distant organ damage in rats with induced injuries, published in Medicina.[5] Vukojevic et al. (2022) reviewed BPC-157's effects on the central nervous system in Neural Regeneration Research, documenting neuroprotective properties across multiple animal models.[6]
The animal data is not the problem. The problem is what comes next.
Why We Have Almost No Human Data
The cancelled Phase I trial
The most significant missing piece of the BPC-157 evidence base is a Phase I clinical trial that was registered, conducted, and then abandoned. PharmaCotherapia, a Croatian pharmaceutical company, sponsored a study designed to evaluate the safety and pharmacokinetics of BPC-157 in 42 healthy volunteers. The trial was completed, but in 2016 the researchers cancelled submission of results. No data was ever published.
The reasons for the cancellation have never been publicly disclosed. This is not uncommon in clinical research; many trials go unpublished for commercial, regulatory, or scientific reasons. But for BPC-157, this represents the single largest opportunity for human safety data that was generated and then withheld from the scientific record.
The pilot studies that do exist
Lee et al. (2024) published a pilot study in Alternative Therapies in Health and Medicine testing BPC-157 in patients with interstitial cystitis. This represents the most substantive published human clinical data for BPC-157, though pilot studies are designed to assess feasibility and preliminary signals, not to establish efficacy.[2]
A separate safety pilot tested intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults, reporting no adverse effects. The sample size of 2 makes this informative only as a preliminary tolerability signal.
No randomized, placebo-controlled trial with adequate power to detect efficacy has been completed and published for any indication.
The single-lab problem
Jozwiak et al. (2025) conducted a literature and patent review of BPC-157's multifunctionality and possible medical applications, published in Pharmaceuticals. Their analysis revealed a pattern that is both the peptide's strength and its most significant limitation: the overwhelming majority of BPC-157 publications originate from a single research group led by Predrag Sikiric at the University of Zagreb in Croatia.[3]
In biomedical research, independent replication by separate laboratories is the gold standard for establishing reliability. A finding published by one group, no matter how many times that group reproduces it, carries less weight than a finding reproduced across multiple independent laboratories. BPC-157's evidence base is largely a single-laboratory body of work.
This does not mean the findings are wrong. The Zagreb group has produced consistent, methodologically detailed animal studies across decades. But it does mean that the standard of evidence has not been met for the kind of confidence that would typically precede clinical development.
Mechanism of action remains unclear
McGuire et al. (2025) published a narrative review titled "Regeneration or Risk?" in Current Reviews in Musculoskeletal Medicine. They noted that BPC-157's mechanism of action remains incompletely understood. Proposed mechanisms include upregulation of growth factor expression (particularly VEGF and EGF), modulation of the nitric oxide system, and interaction with the dopamine and serotonin pathways. But no single mechanism has been definitively established.[7]
For drug development, an unclear mechanism is a significant barrier. Regulatory agencies and pharmaceutical companies need to understand how a drug works to design appropriate clinical trials, predict adverse effects, and identify the right patient populations. How BPC-157 may protect the gut lining through its interaction with nitric oxide is one of the more developed mechanistic threads, but it remains at the "proposed mechanism" stage.
The Regulatory Landscape
FDA Category 2 classification
In 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance. This category indicates that there is insufficient evidence to determine whether the substance would cause harm to humans. The practical consequence: BPC-157 cannot be compounded by commercial pharmacies in the United States.
This classification does not mean BPC-157 is dangerous. It means the FDA has reviewed the available evidence and concluded there is not enough data to support a safety determination. The distinction matters: Category 1 substances are allowed for compounding, Category 2 substances are not, and Category 3 substances are prohibited.
WADA prohibition
The World Anti-Doping Agency prohibits BPC-157 for use in sport. Tian et al. (2023) developed a stable isotope labeling-based strategy for characterizing BPC-157's in vitro metabolic profile specifically for doping control applications, published in Molecules. The study identified key metabolites that could be used for anti-doping detection.[8]
Whitehouse (2025) published a commentary in Inflammopharmacology raising concerns about the gap between BPC-157's cytoprotective claims and its evidence base, specifically questioning why a peptide with such extensive animal data has not progressed through standard clinical development pathways.[9]
What the Systematic Reviews Conclude
Vasireddi et al. (2025) published the most rigorous systematic review of BPC-157 to date, focused on orthopaedic sports medicine applications. Published in HSS Journal, they screened 544 articles and included 36: 35 preclinical animal studies and 1 clinical study. Their conclusion: while preclinical evidence is promising, the near-total absence of human data means BPC-157 should be considered investigational for any clinical application.[1]
McGuire et al. (2025) reached a similar conclusion in their narrative review: the animal evidence is consistent and spans multiple tissue types, but the lack of human trials, the single-laboratory concentration of research, and the unclear mechanism of action collectively prevent any recommendation for clinical use.[7]
Jozwiak et al. (2025) provided the broadest overview, covering both the scientific literature and patent landscape. They identified significant intellectual property activity around BPC-157, suggesting commercial interest exists, but noted the same fundamental evidence gap.[3]
What Needs to Happen
The path from animal evidence to clinical application for BPC-157 would require several things that have not yet occurred:
Independent replication. Laboratories outside the Zagreb group need to reproduce the key findings, particularly the tendon healing, gut protection, and organ protection results. Some independent work has begun, but the volume remains small relative to the original group's output.
Published Phase I safety data. The cancelled PharmaCotherapia trial represents lost data. A new Phase I study, conducted under good clinical practice (GCP) standards, with published results, is the minimum requirement for establishing human safety.
Mechanistic clarity. At least one well-defined mechanism of action, validated across independent studies, would provide the biological rationale needed to design Phase II efficacy trials.
Phase II efficacy trials. Randomized, placebo-controlled trials in specific indications (the most likely candidates being ulcerative colitis, tendon injury, or musculoskeletal healing) with adequate sample sizes.
The ghost trial for BPC-157's Phase II in ulcerative colitis represents another data gap: a trial that was reportedly planned but never materialized in publicly accessible registries.
Bilic et al. (2021) framed BPC-157 within Robert's cytoprotection concept in Journal of Physiology and Pharmacology, arguing that the peptide's complex therapeutic effects warrant a different development paradigm than conventional single-target drug development.[10] Whether regulatory agencies agree with that framing remains to be seen.
What This Does and Does Not Mean
The absence of human trial data does not mean BPC-157 does not work in humans. It means we do not know whether it works in humans. The distinction is not semantic. Animal models predict human outcomes with variable accuracy depending on the condition, the species, the endpoint, and the route of administration.
The animal evidence for BPC-157 is stronger than for most investigational peptides at a similar stage. The consistency of results across dozens of injury models and organ systems is unusual. But consistency within a single laboratory is a weaker form of evidence than consistency across multiple independent groups.
For anyone evaluating BPC-157, the honest assessment is: the preclinical signal is real and consistent, the human data is essentially absent, the mechanism is incompletely understood, and the regulatory status reflects that uncertainty. Until published clinical trial data exists, every claim about BPC-157's effects in humans is an extrapolation from animal studies, whether for gut health, musculoskeletal healing, or any other indication.
The Bottom Line
BPC-157 has generated over 544 published papers and consistent animal data across multiple organ systems and injury models. The human evidence base consists of approximately three pilot studies with small sample sizes. The largest registered Phase I trial was completed but cancelled with no data published. The FDA classified BPC-157 as Category 2 (cannot be compounded commercially), and WADA prohibits its use in sport. The majority of publications originate from a single research group. Independent replication, published Phase I safety data, mechanistic clarity, and Phase II efficacy trials are all needed before the gap between animal evidence and clinical application can be bridged.